Clinical features of ovarian large-cell neuroendocrine carcinoma: Four case reports and review of the literature
- Authors:
- Takafumi Oshita
- Tomomi Yamazaki
- Yumiko Akimoto
- Hirotoshi Tanimoto
- Nobutaka Nagai
- Masaru Mitao
- Akio Sakatani
- Mayumi Kaneko
View Affiliations
Affiliations: Department of Obstetrics and Gynecology, Miyoshi Central Hospital, Miyoshi, Hiroshima, Japan, Department of Obstetrics and Gynecology, Hiroshima City Asa Hospital, Hiroshima, Japan, Department of Pathology, Hiroshima City Asa Hospital, Hiroshima, Japan
- Published online on: August 3, 2011 https://doi.org/10.3892/etm.2011.325
-
Pages:
1083-1090
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The objective of the present study was to present 4 recently encountered ovarian large-cell neuroendocrine carcinoma (LCNEC) cases, and to evaluate their clinicopathological features in the context of the previously reported 29 LCNEC cases. First, we described the clinical features of 4 recently encountered cases. Routine H&E staining and immunohistochemistry for CD56, synaptophysin and chromogranin A were performed on sections of both the LCNEC and epithelial carcinoma components. Clinical data for the total of 33 LCNEC cases were summarized, and the Kaplan-Meier survival curve was estimated. Our cases were observed in women aged 42-81 years. One case is clinically classified as FIGO stage IV with multiple metastases, and the others are classified as FIGO stages Ic, IIc and IIIb by post-surgical findings. Pathological features, assessed by H&E staining, were similar to lung LCNEC, and at least one neuroendocrine marker was positive staining in both LCNEC and the epithelial component. One case was pure type LCNEC and the others were mixed carcinoma. Paclitaxel/carboplatin chemotherapy was performed for all cases and 3 of the 4 treatments were effective. The prognoses of our cases were as follows: 1 in stage Ic died from the disease after only 2 months, but the others survived, with or without recurrence, for 32-64 months, whereas the total 5-year survival of the 33 LCNEC cases was 34.9%. In summary, our 3 LCNEC cases revealed ordinary chemo-sensitivity, resulting in a better prognosis than those previously described, apart from 1 case which exhibited aggressive behavior. For the future, a retrospective survey to elucidate the prognostic factors and prospective clinical studies to evaluate the efficacy of treatment modalities of ovarian LCNEC are necessary, particularly for aggressive LCNEC cases.
View References
1.
|
Tavassoli FA and Devilee P: World Health
Organization Classification of Tumours. Pathology and Genetics of
Tumours of the Breast and Female Genital Organs. IARC Press; Lyon:
2003
|
2.
|
Scully RE, Young RH and Clement PB: Atlas
of Tumor Pathology. Tumors of the Ovary, Maldeveloped Gonads,
Fallopian Tube, and Broad Ligament. Armed Forces Institute of
Pathology; Washington, DC: 1996
|
3.
|
Travis WD, Brambilla E, Muller-Hermelink
HK, et al: World Health Organization Classification of Tumours.
Pathology and Genetics of Tumours of the Lung, Pleura, Thumus and
Heart. IARC Press; Lyon: 2004
|
4.
|
Collins RJ, Cheung A, Ngan HY, et al:
Primary mixed neuroendocrine and mucinous carcinoma of the ovary.
Arch Gynecol Obstet. 248:139–143. 1991. View Article : Google Scholar : PubMed/NCBI
|
5.
|
Khurana KK, Tornos C and Silva EG: Ovarian
neuroendocrine carcinoma associated with a mucinous neoplasm. Arch
Pathol Lab Med. 118:1032–1034. 1994.PubMed/NCBI
|
6.
|
Jones K, Diaz JA and Donner LR:
Neuroendocrine carcinoma arising in an ovarian mucinous
cystadenoma. Int J Gynecol Pathol. 15:167–170. 1996. View Article : Google Scholar : PubMed/NCBI
|
7.
|
Eichhorn JH, Lawrence WD, Young RH, et al:
Ovarian neuroendocrine carcinomas of non-small-cell type associated
with surface epithelial adenocarcinomas. A study of five cases and
review of the literature. Int J Gynecol Pathol. 15:303–314. 1996.
View Article : Google Scholar : PubMed/NCBI
|
8.
|
Chen KT: Composite large-cell
neuroendocrine carcinoma and surface epithelial-stromal neoplasm of
the ovary. Int J Surg Pathol. 8:169–174. 2008. View Article : Google Scholar : PubMed/NCBI
|
9.
|
Ohira S, Itoh K, Shiozawa T, et al:
Ovarian non-small cell neuroendocrine carcinoma with paraneoplastic
parathyroid hormone-related hypercalcemia. Int J Gynecol Pathol.
23:393–397. 2004. View Article : Google Scholar : PubMed/NCBI
|
10.
|
Hirasawa T: Ovarian neuroendocrine
carcinoma associated with mucinous carcinoma and teratoma. Nippon
Rinsho. 62:973–978. 2004.PubMed/NCBI
|
11.
|
Behnam K, Kabus D and Behnam M: Primary
ovarian undifferentiated non-small cell carcinoma, neuroendocrine
type. Gynecol Oncol. 92:372–375. 2004. View Article : Google Scholar : PubMed/NCBI
|
12.
|
Ahmed Z, Aftab K and Kayani N: Ovarian
primary neuroendocrine carcinoma of non-small cell type: report of
an extremely rare neoplasm. J Pak Med Assoc. 55:82–84.
2005.PubMed/NCBI
|
13.
|
Choi YD, Lee JS, Choi C, et al: Ovarian
neuroendocrine carcinoma, non-small cell type, associated with
serous carcinoma. Gynecol Oncol. 104:747–752. 2007. View Article : Google Scholar : PubMed/NCBI
|
14.
|
Lindboe CF: Large cell neuroendocrine
carcinoma of the ovary. APMIS. 115:169–176. 2007. View Article : Google Scholar : PubMed/NCBI
|
15.
|
Veras E, Deavers MT, Silva EG, et al:
Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic
and immunohistochemical study of 11 cases. Am J Surg Pathol.
31:774–782. 2007. View Article : Google Scholar : PubMed/NCBI
|
16.
|
Dundr P, Fischerová D, Povýsil C, et al:
Primary pure large-cell neuroendocrine carcinoma of the ovary.
Pathol Res Pract. 204:133–137. 2008. View Article : Google Scholar : PubMed/NCBI
|
17.
|
Draganova-Tacheva RA, Khurana JS, Huang Y,
et al: Large cell neuroendocrine carcinoma of the ovary associated
with serous carcinoma with mucin production: a case report and
literature review. Int J Clin Exp Pathol. 2:304–309.
2009.PubMed/NCBI
|
18.
|
NCCN Clinical Practice Guidelines in
Oncology (NCCN guidelines TM for Non-Small Cell Lung Cancer).
(http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdfuri).
|